

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

Assignment ID: PATI413632

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	SECURITY INTEREST
CONVEYING PARTY DATA	
Name	Execution Date
PEROSPHERE TECHNOLOGIES INC.	08/08/2024
RECEIVING PARTY DATA	
Company Name:	CONNECTICUT INNOVATIONS, INCORPORATED
Street Address:	470 JAMES STREET, SUITE 8
City:	NEW HAVEN
State/Country:	CONNECTICUT
Postal Code:	06513
PROPERTY NUMBERS Total: 16	
Property Type	Number
Patent Number:	9910053
Patent Number:	10534006
Patent Number:	11243219
PCT Number:	US1549198
Patent Number:	11852639
Application Number:	18512673
Patent Number:	D964569
Application Number:	29866114
Application Number:	63014852
PCT Number:	US2128615
Application Number:	17995930
Application Number:	16144450
Patent Number:	10092641
PCT Number:	US1253145
Application Number:	61529479
Application Number:	62048183
CORRESPONDENCE DATA	
Fax Number:	
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	

Phone: 8605095355
Email: GMONTANO@UKS.COM, GLALLIER@UKS.COM
Correspondent Name: GREGG J. LALLIER, ESQ.
Address Line 1: UPDIKE, KELLY & SPELLACY, P.C.
Address Line 2: 225 ASYLUM STREET, 20TH FLOOR
Address Line 4: HARTFORD, CONNECTICUT 06103

NAME OF SUBMITTER:	Giovanna Montano
---------------------------	------------------

SIGNATURE:	Giovanna Montano
-------------------	------------------

DATE SIGNED:	08/08/2024
---------------------	------------

Total Attachments: 14

source=CII-Perosphere-2024 Loan-IP Security Agr#page1.tiff
source=CII-Perosphere-2024 Loan-IP Security Agr#page2.tiff
source=CII-Perosphere-2024 Loan-IP Security Agr#page3.tiff
source=CII-Perosphere-2024 Loan-IP Security Agr#page4.tiff
source=CII-Perosphere-2024 Loan-IP Security Agr#page5.tiff
source=CII-Perosphere-2024 Loan-IP Security Agr#page6.tiff
source=CII-Perosphere-2024 Loan-IP Security Agr#page7.tiff
source=CII-Perosphere-2024 Loan-IP Security Agr#page8.tiff
source=CII-Perosphere-2024 Loan-IP Security Agr#page9.tiff
source=CII-Perosphere-2024 Loan-IP Security Agr#page10.tiff
source=CII-Perosphere-2024 Loan-IP Security Agr#page11.tiff
source=CII-Perosphere-2024 Loan-IP Security Agr#page12.tiff
source=CII-Perosphere-2024 Loan-IP Security Agr#page13.tiff
source=CII-Perosphere-2024 Loan-IP Security Agr#page14.tiff

INTELLECTUAL PROPERTY SECURITY AGREEMENT

This **INTELLECTUAL PROPERTY SECURITY AGREEMENT** (this “**Agreement**”) is made as of August 8, 2024 between **PEROSPHERE TECHNOLOGIES INC.**, a Delaware corporation (the “**Debtor**”) and **CONNECTICUT INNOVATIONS, INCORPORATED** (the “**Secured Party**”).

W I T N E S S E T H

WHEREAS, pursuant to the terms of a certain Loan and Warrant Purchase Agreement dated as of the date hereof between Debtor and Secured Party (as amended and in effect, the “**Loan Agreement**”), Secured Party has agreed to make a loan in the principal amount of \$1,500,000 (the “**Loan**”) to Debtor, which Loan is evidenced by a Secured Promissory Note (the “**Note**”); and

WHEREAS, pursuant to that certain Security Agreement between Debtor and Secured Party dated as of the date hereof (as amended and in effect from time to time, the “**Security Agreement**”), Debtor has granted to the Secured Party a security interest in the Collateral (as defined by the Security Agreement), including without limitation the Domain Names, Trademarks, Patents and Copyrights (each as defined herein), listed on **Schedule A** attached hereto, all to secure the payment and performance of the Obligations (as defined in the Security Agreement); and

WHEREAS, this Agreement is supplemental to the provisions contained in the Security Agreement;

NOW, THEREFORE, in consideration of the premises contained herein and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto hereby agree as follows:

1. DEFINITIONS. Unless otherwise defined herein, terms which are defined in the Security Agreement and used herein are so used as so defined. The following terms shall have the following meanings:

“**Copyrights**” means (a) all copyrights of the United States or any other country, including, without limitation, any thereof referred on **Schedule A** attached hereto; and (b) all copyright registrations filed in the United States or in any other country, including, without limitation, any thereof referred to on **Schedule A** attached hereto.

“**Domain Names**” means all domain names and domain name registration applications that are owned by Debtor or in which Debtor has any right, title or interest, now or in the future, including but not limited to all derivatives or variations, whether authorized or unauthorized, including those listed on **Schedule A** attached hereto.

“**Event of Default**” shall have the same meaning set forth in the Loan Agreement.

“**Patents**” means (a) all letters patent of the United States and all reissues and extensions thereof; and (b) all applications for letters patent of the United States and all divisions, continuations and continuations-in-part thereof or any other country, including, without limitation, any thereof referred to on **Schedule A** attached hereto.

“Registry” means, as applicable, (a) any domain name registry with whom the Domain Names are registered, (b) the U.S. Copyright Office or any comparable office of any foreign jurisdiction with whom Copyrights are registered or (c) the U.S. Patent & Trademark Office or any comparable office of any state or foreign jurisdiction with whom Trademarks or Patents are registered.

“Trademarks” means (a) all trademarks, trade names, corporate names, company names, business names, fictitious business names, trade styles, service marks, logos and other source or business identifiers and the goodwill associated therewith, now existing or hereafter adopted or acquired, all registrations and recordings thereof, and all applications in connection therewith (and the goodwill associated therewith), trademark and service mark registrations and registration applications, whether registered in the U.S. Patent and Trademark Office or in any similar office or agency of the United States, any State thereof or any other country or any political subdivision thereof or otherwise, including, without limitation, any thereof referred to on **Schedule A** attached hereto; (b) all renewals thereof; and (c) all goodwill of the business connected with the use of and symbolized by the Trademarks.

2. SECURITY INTEREST.

2.1. Security Interest. As collateral security for the payment and performance in full of all of the Obligations, Debtor hereby unconditionally grants to the Secured Party a continuing security interest in and lien on the Domain Names, Trademarks, Patents and Copyrights that constitute Collateral, and all Proceeds (as defined in the Security Agreement) of any of the foregoing. Debtor hereby authorizes the Secured Party to take other appropriate steps to transfer effective ownership and control of such Domain Names, Trademarks, Patents and Copyrights, with the respective Registry upon the occurrence and during the continuance of an Event of Default and the exercise of the remedies of the Secured Party under this Agreement and the Security Agreement.

2.2. Supplemental Security Agreement. Pursuant to the Security Agreement, Debtor has granted to the Secured Party a continuing security interest in and lien on the Collateral (including certain Domain Names, Trademarks, Patents and Copyrights). The Security Agreement, and all rights and interests of the Secured Party in and to the Collateral (including such Domain Names, Trademarks, Patents and Copyrights) thereunder, are hereby ratified and confirmed in all respects, and are hereby incorporated herein by reference thereto. In no event shall this Agreement, the grants hereunder, or the recordation of this Agreement (or any document hereunder) with the respective Registry adversely affect or impair, in any way or to any extent, the Security Agreement, the security interest of the Secured Party in the Collateral (including the Domain Names, Trademarks, Patents and Copyrights that constitute Collateral) pursuant to the Security Agreement and this Agreement, the attachment and perfection of such security interest under the UCC (including the security interest in such Domain Names, Trademarks, Patents and Copyrights), or any present or future rights and interests of the Secured Party in and to the Collateral under or in connection with the Security Agreement, this Agreement or the UCC. Any and all rights and interests of the Secured Party in and to the Domain Names, Trademarks, Patents and Copyrights that constitute Collateral (and any and all Obligations of Debtor with respect to

such Domain Names, Trademarks, Patents and Copyrights) provided herein, or arising hereunder or in connection herewith, shall only supplement and be cumulative and in addition to the rights and interests of the Secured Party (and the Obligations of Debtor) in, to or with respect to the Collateral (including such Domain Names, Trademarks, Patents and Copyrights) provided in or arising under or in connection with the Security Agreement and shall not be in derogation thereof. THE SECURED PARTY DOES NOT ASSUME ANY LIABILITY ARISING IN ANY WAY BY REASON OF HOLDING SUCH COLLATERAL.

3. AFTER-ACQUIRED INTELLECTUAL PROPERTY.

3.1. After-Acquired Domain Names, Copyrights, Trademarks and Patents. If, before the Obligations shall have been finally paid and satisfied in full, Debtor shall obtain any right, title or interest in or to any other or new Domain Names, Trademarks, Copyrights or Patents that constitute Collateral, or become entitled to the benefit of any such Domain Names, Trademarks, Copyrights or Patents or any variation or improvement on any of such Collateral, the provisions of this Agreement and the Security Agreement shall automatically apply thereto and Debtor shall promptly give to the Secured Party notice thereof in writing and execute and deliver to the Secured Party such documents or instruments as the Secured Party may reasonably request further to implement, preserve or evidence the interests of the Secured Party therein.

3.2. Amendment to Schedule. Debtor authorizes the Secured Party to modify this Agreement, without the necessity of Debtor's further approval or signature, solely by amending **Schedule A** hereto to include any future or other Domain Names, Trademarks, Copyrights or Patents under Section 2 or Section 3 hereof that constitute Collateral and/or to delete Domain Names, Trademarks, Copyrights or Patents terminated by Debtor pursuant to the Security Agreement.

4. NO ASSUMPTION OF LIABILITY. NOTWITHSTANDING ANYTHING TO THE CONTRARY CONTAINED HEREIN, THE SECURED PARTY DOES NOT ASSUME ANY LIABILITIES OF THE DEBTOR WITH RESPECT TO ANY CLAIM OR CLAIMS REGARDING THE DEBTOR'S OWNERSHIP OR PURPORTED OWNERSHIP OF, OR RIGHTS OR PURPORTED RIGHTS ARISING FROM, ANY OF THE DOMAIN NAMES, COPYRIGHTS, TRADEMARKS OR PATENTS THAT CONSTITUTE COLLATERAL, OR ANY PRACTICE, USE, LICENSE OR SUBLICENSE THEREOF, WHETHER ARISING OUT OF ANY PAST, CURRENT OR FUTURE EVENT, CIRCUMSTANCE, ACT OR OMISSION OR OTHERWISE. ALL OF SUCH LIABILITIES SHALL BE EXCLUSIVELY BORNE BY THE DEBTOR, AND THE DEBTOR SHALL INDEMNIFY THE SECURED PARTY FOR ANY AND ALL COSTS, EXPENSES, DAMAGES AND CLAIMS, INCLUDING REASONABLE LEGAL FEES, INCURRED BY THE SECURED PARTY WITH RESPECT TO SUCH LIABILITIES.

5. RIGHTS AND REMEDIES CUMULATIVE. The rights and remedies of the Secured Party with respect to the Domain Names, Copyrights, Trademarks and Patents that constitute Collateral, whether established hereby, by the Security Agreement or by any other agreements or by law, shall be cumulative and may be exercised singularly or concurrently. This Agreement is supplemental to the Security Agreement, and nothing contained herein shall in any way derogate

from any of the rights or remedies of the Secured Party contained therein. Nothing contained in this Agreement shall be deemed to extend the time of attachment or perfection of or otherwise impair the security interest in any of the Collateral granted to the Secured Party under the Security Agreement.

6. **AMENDMENT AND WAIVER.** This Agreement may only be amended, and any provision hereunder may only be waived, pursuant to the Security Agreement.

7. **FILINGS.** The Secured Party may at any time and from time to time, at Debtor's expense, file, or have Secured Party's representatives or agents file, a copy of this Agreement with the U.S. Patent & Trademark Office, the U.S. Copyright Office or any other filing authority.

8. **COUNTERPARTS.** This Agreement may be executed in any number of counterparts, and each such counterpart hereof shall be deemed to be an original instrument, but all such counterparts together shall constitute but one agreement (notwithstanding that all of the parties are not signatories to the original or the same counterpart, or that signature pages from different counterparts are combined), and it shall not be necessary when making proof of this Agreement or any counterpart thereof to account for any other counterpart, and the signature of any party to any counterpart shall be deemed to be a signature to and may be appended to any other counterpart. For purposes of this Agreement, a document (or signature page thereto) signed and transmitted by facsimile machine or other electronic means is to be treated as an original document. The signature of any party on any such document, for purposes hereof, is to be considered as an original signature, and the document transmitted is to be considered to have the same binding effect as an original signature on an original document. At the request of any party, any facsimile or other electronic signature is to be re-executed in original form by the party which executed the facsimile or other electronic signature. No party may raise the use of a facsimile machine or other electronic means, or the fact that any signature was transmitted through the use of a facsimile machine or other electronic means, as a defense to the enforcement of this Agreement.


[Intentionally Left Blank - Signature Page(s) to Follow]

[Signature Page to Intellectual Property Security Agreement]

IN WITNESS WHEREOF, the foregoing Intellectual Property Security Agreement is signed and delivered on the date first set forth above.

DEBTOR:

PEROSPHERE TECHNOLOGIES INC.

By: 
Name: Sasha Bakhu
Title: CEO

SECURED PARTY:

CONNECTICUT INNOVATIONS, INCORPORATED

By: _____
Name: _____
Title: Senior Managing Director, Investments

[Signature Page to Intellectual Property Security Agreement]

IN WITNESS WHEREOF, the foregoing Intellectual Property Security Agreement is signed and delivered on the date first set forth above.


DEBTOR:

PEROSPHERE TECHNOLOGIES INC.

By: _____
Name:
Title:

SECURED PARTY:

CONNECTICUT INNOVATIONS, INCORPORATED

By:  _____
Name: Peter Longo
Title: Senior Managing Director, Investments

Schedule A

Technology and Intellectual Property

All of Debtor's right, title and interest in and to its Technology and Intellectual Property. "Technology and Intellectual Property" shall mean all know-how, show how, technology, inventions, developments, trade secrets, computer programs (including the models, algorithms, source and object code thereto), customer lists, trade names, trade name rights, trademarks and service marks (and the goodwill associated therewith), trademark and service mark rights, trademark and service mark registrations and registration applications, patents, patent rights, patent applications, copyrights, and copyright registrations and registration applications, all licenses in connection with any of the foregoing, all reissues, divisions, continuations, extensions, renewals and continuations-in-part of any of the foregoing, and all rights in connection therewith including all claims against third parties for past, present or future infringement of any of the foregoing; all licenses, permits, and agreements of any kind or nature pursuant to which Debtor possesses, uses or has authority to possess or use intangible property of others, or others possess, use or have authority to possess or use intangible property of Debtor; and all recorded data of any kind or nature regardless of the medium of recording, including without limitation all software, code, writings, plans, specifications and schematics, whether now owned or hereafter acquired or arising, including but not limited to the following patents, copyrights and trademarks:

Patents

Case Ref.	Application Number	Application Date	Country	Case Status	Due Date/Next Action	Registration No.	Registration Date
PER 109 - Microfluidic Chip-Based, Universal Coagulation Assay - Patent claims are directed to a microchip for blood and plasma coagulation time measurement, the reader device and microchip for blood and plasma coagulation time measurement and methods of using the same.							
PER109/NAT/US	14/849,348	9/9/2015	US	Issued		9,910,053	03/06/18
PER/CON/US	15/909,677	3/1/2018	US	Issued		10,534,006	01/14/20
PER/CON2/US	16/738,863	1/9/2020	US	Issued		11243219	02/08/22
PER/CON3/US	17/590,944	2/2/2022	US	Issued		11852639	12/26/23
PER109/PCT/WO	PCT/US2015/049198	9/9/2015	PCT	Gone National	N/A		
PER109/PRO/US	62/048,183	9/9/2014	US	Expired at end of life	N/A		
PER109/XP2/AE	P6000254/17	9/9/2015	United Arab Emirates	Issued		3339	09/11/20

Schedule A
Page 2

Case Ref.	Application Number	Application Date	Country	Case Status	Due Date/Next Action	Registration No.	Registration Date
PER109/XP2/AP	AP/P2017/009807	9/9/2015	African Regional Intellectual Property Organisation	Issued		5545	04/14/21
PER109/XP2/AU	2015315159	9/9/2015	Australia	Issued		2015315159	04/18/19
PER109/XP2/BH	042/17	9/9/2015	Bahrain	Issued		1849	09/05/22
PER109/XP2/BR	BR 11 2017 0045060	9/9/2015	Brazil	Pending	Response to OA filed 1/3/20		
PER109/XP2/CA	2,959,742	9/9/2015	Canada	Issued		2959742	08/20/19
PER109/XP2/CL	00546-2017	9/9/2015	Chile	Issued		59971	07/08/20
PER109/XP2/CN	201580060192.8	9/9/2015	China	Issued		ZL201580060192.8	04/30/21
PER109/XP2/CO	NC2017/0003282	9/9/2015	Colombia	Issued		37107	02/24/20
PER109/XP2/CR	2017-0133	9/9/2015	Costa Rica	Issued		004319	01/09/23
PER109/XP2/EA	201790443	9/9/2015	Eurasia	Issued		033382	10/31/19
PER109/XP2/EC	IEPI-2017-20834	9/9/2015	Ecuador	Pending	Awaiting first Office Action;		
					vol.amend filed 7/24/20		
PER109/XP2/EG	348/2017	9/9/2015	Egypt	Issued	Working required by 2/12/23	29673	02/12/20
PER109/NAT/HK-EP	18100179.3	9/9/2015	Hong Kong	Issued	Annuity due 9/9/26	1240649	05/25/23
PER109/XP2/EP	15767657.8	9/9/2015	EPO	Issued	Opposition period expired	3191836	11/23/22
PER109/XP2/AL	15767657.8	9/9/2015	Albania	Issued		3191836	
PER109/XP2/AT	15767657.8	9/9/2015	Austria	Issued		1533437	
PER109/XP2/BE	15767657.8	9/9/2015	Belgium	Issued		3191836	
PER109/XP2/BG	15767657.8	9/9/2015	Bulgaria	Issued		3191836	

Schedule A
Page 3

Case Ref.	Application Number	Application Date	Country	Case Status	Due Date/Next Action	Registration No.	Registration Date
PER/109/XP2/CH	15767657.8	9/9/2015	Switzerland	Issued		3191836	
PER/109/XP2/CY	15767657.8	9/9/2015	Cyprus	Issued		3191836	
PER/109/XP2/CZ	15767657.8	9/9/2015	Czechia	Issued		3191836	
PER/109/XP2/DE	15767657.8	9/9/2015	Germany	Issued		602015081690	
PER/109/XP2/DK	15767657.8	9/9/2015	Denmark	Issued		3191836	
PER/109/XP2/EE	15767657.8	9/9/2015	Estonia	Issued		3191836	
PER/109/XP2/FI	15767657.8	9/9/2015	Finland	Issued		3191836	
PER/109/XP2/FR	15767657.8	9/9/2015	France	Issued		3191836	
PER/109/XP2/GB	15767657.8	9/9/2015	Great Britain	Issued		3191836	
PER/109/XP2/GR	15767657.8	9/9/2015	Greece	Issued		20230400291	
PER/109/XP2/HR	15767657.8	9/9/2015	Croatia	Issued		P20230171T	
PER/109/XP2/HU	15767657.8	9/9/2015	Hungary	Issued		3191836	
PER/109/XP2/IE	15767657.8	9/9/2015	Ireland	Issued		3191836	
PER/109/XP2/IS	15767657.8	9/9/2015	Iceland	Issued		3191836	
PER/109/XP2/IT	15767657.8	9/9/2015	Italy	Issued		502023000007518	
PER/109/XP2/LT	15767657.8	9/9/2015	Lithuania	Issued		3191836	
PER/109/XP2/LU	15767657.8	9/9/2015	Luxembourg	Issued		3191836	
PER/109/XP2/LV	15767657.8	9/9/2015	Latvia	Issued		3191836	
PER/109/XP2/MC	15767657.8	9/9/2015	Monaco	Issued		3191836	
PER/109/XP2/MK	15767657.8	9/9/2015	North Macedonia	Issued		P-2022/622	
PER/109/XP2/MT	15767657.8	9/9/2015	Malta	Issued		3191836	
PER/109/XP2/NL	15767657.8	9/9/2015	Netherlands	Issued		3191836	
PER/109/XP2/NO	15767657.8	9/9/2015	Norway	Issued		3191836	
PER/109/XP2/PL	15767657.8	9/9/2015	Poland	Issued		3191836	
PER/109/XP2/PT	15767657.8	9/9/2015	Portugal	Issued		3191836	
PER/109/XP2/RO	15767657.8	9/9/2015	Romania	Issued		3191836	
PER/109/XP2/RS	15767657.8	9/9/2015	Serbia	Issued		P-2023/126	

Schedule A
Page 4

Case Ref.	Application Number	Application Date	Country	Case Status	Due Date/Next Action	Registration No.	Registration Date
PER109/XP2/SI	15767657.8	9/9/2015	Slovenia	Issued		SI201531909	
PER109/XP2/SK	15767657.8	9/9/2015	Slovakia	Issued		SM-T-202300041	
PER109/XP2/SM	15767657.8	9/9/2015	San Marino	Issued		3191836	
PER109/XP2/TR	15767657.8	9/9/2015	Turkey	Issued		2022/021906	
PER109/XP2/ES	15767657.8	9/9/2015	Spain	Issued		3191836	
PER109/XP2/SE	15767657.8	9/9/2015	Sweden	Issued		3191836	
PER109/DIV/EP	22179477.9	6/16/2022	EPO	Pending	Request exam, pay exam and designation fees, and response to search opinion due 6/28/23		
PER109/DIV/EP/HK	42023074298.3	6/9/2023	Hong Kong	Pending	annuity due 9/9/28		
PER109/XP2/ID	PID 2017 02147	9/9/2015	Indonesia	Abandoned	Pabst firm failed to notify us of grant and annuities where not paid. Pabst		
					firm is presently researching means of revival.		
PER109/XP2/IL	250977	9/9/2015	Israel	Issued		250977	07/31/20
PER109/XP2/IN	201737008962	9/9/2015	India	Pending	Awaiting status update		
PER109/XP2/JP	2017-513081	9/9/2015	Japan	Issued		6550126	07/05/19
PER109/XP2/KR	2017-7009394	9/9/2015	Republic of Korea	Issued		10-2533127	05/11/23
PER109/XP2/MX	MX/a/2017/003043	9/9/2015	Mexico	Issued	Annuity due 9/9/27	393492	06/27/22

Schedule A
Page 5

Case Ref.	Application Number	Application Date	Country	Case Status	Due Date/Next Action	Registration No.	Registration Date
PER109/XP2/NZ	730056	9/9/2015	New Zealand	Issued		730056	01/29/19
PER109/XP2/OA	1201700078	9/9/2015	African Intellectual Property Organisation	Pending	Awaiting first Office Action		
PER109/XP2/OM	OM/P/2017/00062	9/9/2015	Oman	Issued		000388	12/27/20
PER109/XP2/PE	000437-2017/DIN	9/9/2015	Peru	Allowed	Awaiting Receipt of Letters Patent		
PER109/XP2/PH	1-2017-500415	9/9/2015	Philippines	Allowed	Notice of Allowance issued 6/19/23		
PER109/XP2/QA	QA/201703/00100	9/9/2015	Qatar	Allowed	Fees paid for grant on 1/25/22		
PER109/XP2/SA	517381058	3/9/2017	Saudi Arabia	Pending	Response to OA filed 5/2/20		
PER109/XP2/SG	11201701596W	9/9/2015	Singapore	Issued		11201701596W	02/08/19
PER109/XP2/TH	1701001240	9/9/2015	Thailand	Pending	Request for Exam filed 3/15/23 relying on JP patent		
PER109/XP2/UA	A201702034	9/9/2015	Ukraine	Issued		118986	04/10/19
PER109/XP2/VN	1-2017-01241	9/9/2015	Vietnam	Issued		33913	10/04/22
PER109/XP2/ZA	2017-02431	9/9/2015	South Africa	Issued		2017/02431	08/29/18
PER109/CON4/US	18512.673	11/17/2023	US	Pending			
PER 110 - Coagulumeter Design Patent							
PER110/US	29/717,686	12/18/19	US	Issued		D964569	09/20/22
PER110/DIV	29/866,114	08/29/22	US	Pending			
Whole Blood Control System							

Schedule A
Page 6

Case Ref.	Application Number	Application Date	Country	Case Status	Due Date/Next Action	Registration No.	Registration Date
145574.521625	63/014,852	4/24/20	US	Expired at end of life			
145574.539094	PCT/US2021/0286 15	4/22/21	PCT	Pending	Entry into national stage due 10/24/22; Instructions provided to enter US, CA, MX, AU, CN, JP and EP		
145574.568276 AU	2021260947	4/22/21	AU	Pending	Request exam due 4/22/26 and annuity due 4/22/25		
145574.568277 CA	CA 180974	4/22/21	CA	Pending			
145574.568278 CN	202180030107.9	4/22/21	CN	Pending			
145574.568279 EP	21733241.0	4/22/21	EPO	Pending			
145574.577361 HK	62023070623.1	4/22/21	HK	Pending			
145574.568280 JP	2022-565581	4/22/21	JP	Pending	Substantive request for exam due 4/22/24		
145574.568281 MX	MX/a/2022/013141	4/22/21	MX	Pending			
145574.568275 US	17/995,930	4/22/21	US	Pending			
PER 102 - Methods For Effectively and Rapidly Desensitizing Allergic Patients - Patent claims are directed to a method of intradermally injecting microparticles of chitosan and chitosan derivatives that include one or more antigens to desensitize people to allergens. The method is advantageous as the microparticles provide that a significant amount of the one or more antigens injected are not released until uptake by the macrophages in the lymph system.							
PER102/CON(2)/US	16/144,450	9/27/2018	US	Abandoned			
PER102/CON/US	15/480,564	4/6/2017	US	Issued		10,092,641	10/09/18
PER102/DIV/AU	2018200963	2/9/2018	Australia	Issued		2018200963	06/11/20
PER102/PCT/WO	PCT/US2012/053145	8/30/2012	PCT	Gone National			

Case Ref.	Application Number	Application Date	Country	Case Status	Due Date/Next Action	Registration No.	Registration Date
PER102/PRO/US	61/529,479	8/31/2011	US	Expired at end of life			
PER102/XP2/AU	2012301814	8/30/2012	Australia	Abandoned			
PER102/XP2/CA	2,846,858	8/30/2012	Canada	Issued		2846858	03/08/22
PER102/XP2/EP	12828090.6	8/30/2012	EPO	Issued		2750705	11/16/22
PER102/XP2/CH	12828090.6	8/30/2012	Switzerland	Issued		2750705	
PER102/XP2/DE	12828090.6	8/30/2012	Germany	Issued		602012079017.2	
PER102/XP2/DK	12828090.6	8/30/2012	Denmark	Issued		2750705	
PER102/XP2/FR	12828090.6	8/30/2012	France	Issued		2750705	
PER102/XP2/GB	12828090.6	8/30/2012	Great Britain	Issued		2750705	
PER102/XP2/IE	12828090.6	8/30/2012	Ireland	Issued		2750705	
PER102/XP2/IT	12828090.6	8/30/2012	Italy	Issued		2750705	
PER102/XP2/NL	12828090.6	8/30/2012	Netherlands	Issued		2750705	
PER102/XP2/ES	12828090.6	8/30/2012	Spain	Issued		12828090.6	

Trademarks

Case Ref.	Application Number	Application Date	Country	Case Status	Due Date/Next Action	Registration No.	Registration Date
Trademarks for Coagulometer, Cuvettes and Whole Blood Controls							
Ref No.	Mark	Application No.	Filing Date	Status	Due Date/Next Action	Registration No.	Reg. Date
145574-584500	Perosphere	EUTM 018923797	9/11/2023	pending classes 5,9 + 10			
145574-584502	Logo + Perosphere	EUTM 018923786	9/11/2023	pending classes 5,9 + 10			

Schedule A
Page 8

Case Ref.	Application Number	Application Date	Country	Case Status	Due Date/Next Action	Registration No.	Registration Date
145574-584503	ClotChek	EUTM 018923854	9/11/2023	pending classes 5,9 + 10			
145574-584504	ClotChek + Logo	EUTM 018923854	9/11/2023	pending classes 5,9 + 10			
145574-587024	Perosphere	US No. 98267524	11/10/2023	pending classes 5,9 + 10			
145574-587025	Logo + Perosphere	US No. 98267522	11/10/2023	pending classes 5,9 + 10			
145574-587026	ClotChek	US No. 98267521	11/10/2023	pending classes 5,9 + 10			
145574-587027	ClotChek + Logo	US No. 98267518	11/10/2023	pending classes 5,9 + 10			

Domain Names:

- www.perospheretech.com
- www.clotchek.com

PATENT

REEL: 068229 FRAME: 0086

RECORDED: 08/08/2024